ArticleInfection and drug resistance2022
Effect of Mixed Infections with
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 21 citations in OpenAlex.
- Diagnostic Discordance During MDR-TB Treatment: Retrospective Identification ofMicroorganisms · 2026Article
- Distribution of Non-Tuberculous Mycobacterium Species in Pulmonary and Extrapulmonary Infections in South India-A Retrospective Analysis.Microorganisms · 2026Article
- Molecular detection of incidental Mycobacterium tuberculosis and nontuberculous mycobacteria co-detections using DNA strip assay: a laboratory-based study.Scientific reports · 2026Article
- Molecular epidemiology of non-tuberculous mycobacteria in clinical samples from Jiangxi Province, 2021-2023.BMC microbiology · 2026Article
- Secondary infections following tuberculosis: epidemiology, pathogenesis and clinical implications.Breathe (Sheffield, England) · 2026Review
- Dual Mycobacterial Infection: Rare Coinfection of Mycobacterium tuberculosis and Nontuberculous Mycobacteria.Cureus · 2026Article
- Negligible clinical impact of subsequent non-tuberculous mycobacteria isolation during MDR/RR-TB treatment: a 9-year retrospective cohort study from Wenzhou, China.BMC infectious diseases · 2025Article
- Simultaneous detection and differentiation ofMicrobiology spectrum · 2025Article
- Demixer: a probabilistic generative model to delineate different strains of a microbial species in a mixed infection sample.Bioinformatics (Oxford, England) · 2025Article
- Colonization or coinfection? A case report ofASM case reports · 2025Article
- Targeted enzymes delivered by liposomes could address an unmet need in mycobacterial respiratory infections.Future microbiology · 2025Article
- Comparison of molecular testing methods for diagnosing non-tuberculous mycobacterial infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Status and outlook of pulmonary tuberculosis coinfection.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Review
- Toward better cures forClinical microbiology reviews · 2024Review
- Article
- Prevalence of nontuberculous mycobacteria and the emergence of rare species in Henan Province, China.Epidemiology and infection · 2024Article
- Article
- Comprehensive genomic surveillance reveals transmission profiles of extensively drug-resistant tuberculosis cases in Pará, Brazil.Frontiers in microbiology · 2024Article
- Evaluation of nucleotide MALDI-TOF-MS for the identification ofFrontiers in cellular and infection microbiology · 2024Article
- The positivity rates and drug resistance patterns ofFrontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorrect species identification is essential before initiation of TB treatment, due to substantial drug susceptibility profile differences among mycobacterial species. Given that nontuberculous mycobacteria (NTM) are frequently resistant to first-line anti-tuberculosis drugs, cases with mixed infections with
methodsFrom January 2019 through December 2019, we retrospectively collected MDR-TB isolates from three TB specialised hospitals. Species identifications of isolates were performed using the MeltPro Myco assay.
resultsA total of 837 MDR-TB isolates were analysed, of which 22 isolates (2.6%) were found to contain a mixture of NTM and MTB organisms. Significant differences in prevalence rates of mixed infections across regions were observed, with prevalence rates ranging from 0.0% (0/213) in Beijing to 3.4% (12/353) in Fuzhou to 3.7% (10/271) in Guangzhou. Among the 22 patients with NTM-TB mixed infections, a total of five different mycobacterial species were identified, of which the most prevalent species was
conclusionThe results reported here demonstrated that mixed infections with MTB and NTM occurred in approximately 3% of suspected MDR-TB patients in China. These findings raise concerns about the accuracy of molecular diagnostics-based species identification tests and draw attention to the possibility that NTM-MTB mixed infections will be misdiagnosed as MDR-TB in high TB burden settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.